Article in Circulation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Omar Brito-EstradaDivision of Molecular Cardiovascular Biology, The Heart Institute (O.B.-E., Y.K., A.M.G., K.R.H., M.L.K., J.P.V., N.S.B., J.H., J.D.M., C.A.M.), Cincinnati Children's Hospital Medical Center, Cincinnati, OH.ORCID 0000-0002-8856-6791
Yasuhide KuwabaraDivision of Molecular Cardiovascular Biology, The Heart Institute (O.B.-E., Y.K., A.M.G., K.R.H., M.L.K., J.P.V., N.S.B., J.H., J.D.M., C.A.M.), Cincinnati Children's Hospital Medical Center, Cincinnati, OH.ORCID 0000-0002-9493-9494
Aaron M GibsonDivision of Molecular Cardiovascular Biology, The Heart Institute (O.B.-E., Y.K., A.M.G., K.R.H., M.L.K., J.P.V., N.S.B., J.H., J.D.M., C.A.M.), Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Keira R HasselDivision of Molecular Cardiovascular Biology, The Heart Institute (O.B.-E., Y.K., A.M.G., K.R.H., M.L.K., J.P.V., N.S.B., J.H., J.D.M., C.A.M.), Cincinnati Children's Hospital Medical Center, Cincinnati, OH.ORCID 0000-0003-1082-0603
Michael L KamradtDivision of Molecular Cardiovascular Biology, The Heart Institute (O.B.-E., Y.K., A.M.G., K.R.H., M.L.K., J.P.V., N.S.B., J.H., J.D.M., C.A.M.), Cincinnati Children's Hospital Medical Center, Cincinnati, OH.ORCID 0000-0002-0628-1988
Joseph P VerryDivision of Molecular Cardiovascular Biology, The Heart Institute (O.B.-E., Y.K., A.M.G., K.R.H., M.L.K., J.P.V., N.S.B., J.H., J.D.M., C.A.M.), Cincinnati Children's Hospital Medical Center, Cincinnati, OH.ORCID 0000-0003-0751-5683
N Scott BlairDivision of Molecular Cardiovascular Biology, The Heart Institute (O.B.-E., Y.K., A.M.G., K.R.H., M.L.K., J.P.V., N.S.B., J.H., J.D.M., C.A.M.), Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Michael J BroundDepartment of Pediatrics (Y.K., J.D.M., C.A.M.), University of Cincinnati College of Medicine, Cincinnati, OH.ORCID 0000-0003-3238-5489
Jiuzhou HuoDivision of Molecular Cardiovascular Biology, The Heart Institute (O.B.-E., Y.K., A.M.G., K.R.H., M.L.K., J.P.V., N.S.B., J.H., J.D.M., C.A.M.), Cincinnati Children's Hospital Medical Center, Cincinnati, OH.ORCID 0000-0003-3242-568X
Jeffery D MolkentinDivision of Molecular Cardiovascular Biology, The Heart Institute (O.B.-E., Y.K., A.M.G., K.R.H., M.L.K., J.P.V., N.S.B., J.H., J.D.M., C.A.M.), Cincinnati Children's Hospital Medical Center, Cincinnati, OH.ORCID 0000-0002-3558-6529
Catherine A MakarewichDivision of Molecular Cardiovascular Biology, The Heart Institute (O.B.-E., Y.K., A.M.G., K.R.H., M.L.K., J.P.V., N.S.B., J.H., J.D.M., C.A.M.), Cincinnati Children's Hospital Medical Center, Cincinnati, OH.ORCID 0000-0001-6907-4401
Funding
Molecular examination of mitochondrial calcium controlR01HL132831 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI BERS, DONALD M, MOLKENTIN, JEFFERY D · 2016 to 2024
$5.9M
Understanding Cardiovascular Disease MechanismsT32HL125204 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI Evangelia G Kranias, Jeffery D Molkentin · 2015 to 2026
$3.4M
Microprotein Regulation of Mitochondrial FunctionR01HL160569 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI Catherine A Makarewich · 2022 to 2026
$2.0M
Developing DWORF gene therapy to treat heart failure and muscular dystrophyR01HL171221 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI Catherine A Makarewich, Jeffery D Molkentin · 2024 to 2026
$1.8M
Mitochondrial Regulation of Calcium Homeostasis and Cell Death in Muscular DystrophyR00AR078253 · NIAMS · BAYLOR COLLEGE OF MEDICINE · PI Michael Bround · 2024 to 2026
$727k
Determining the regulatory role of microprotein ALN on SERCA2a and heart contractilityF30HL172585 · NHLBI · UNIVERSITY OF CINCINNATI · PI Keira Hassel · 2024 to 2026
methodsTransgenic and adeno-associated virus approaches were used to overexpress DWORF in the heart. Mice underwent transverse aortic constriction (TAC) to model pressure overload-induced heart failure. Cardiac function, mitochondrial metabolism, SR Ca
resultsMitochondria from DWORF transgenic hearts displayed increased basal respiration, maximal respiration, and spare respiratory capacity, correlating with enhanced mitochondrial Ca
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
DWORF Gene Therapy Improves Cardiac Calcium Handling and Mitochondrial Function. · full record | Socratic